08:38 AM EDT, 08/12/2024 (MT Newswires) -- LENZ Therapeutics ( LENZ ) said Monday it has submitted a new-drug application to the US Food and Drug Administration for LNZ100, which is intended to improve near vision in people with presbyopia.

The biopharmaceutical company said the application is supported by a phase 3 study of LNZ100 to treat presbyopia, which met all primary and secondary near vision improvement endpoints.

The FDA has a 60-day filing review period to determine whether the submission is complete and acceptable for review, the company said.